JO
PRME icon

John Overdeck’s Prime Medicine PRME Stock Holding History

John Overdeck’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.63M Sell
1,524,511
-48,300
-3% -$160K ﹤0.01% 2026
2026
Q1 		$5.47M Sell
1,572,811
-56,513
-3% -$215K ﹤0.01% 1902
2025
Q4 		$5.65M Buy
1,629,324
+1,181,657
+264% +$5.26M 0.01% 1600
2025
Q3 		$2.48M Buy
447,667
+189,244
+73% +$769K ﹤0.01% 1987
2025
Q2 		$638K Sell
258,423
-347
-0.1% -$535 ﹤0.01% 2475
2025
Q1 		$515K Buy
258,770
+92,571
+56% +$236K ﹤0.01% 2510
2024
Q4 		$485K Sell
166,199
-152,374
-48% -$535K ﹤0.01% 2552
2024
Q3 		$1.23M Sell
318,573
-362,903
-53% -$1.68M ﹤0.01% 1997
2024
Q2 		$3.5M Buy
681,476
+173,398
+34% +$1.05M 0.01% 1183
2024
Q1 		$3.56M Buy
508,078
+239,716
+89% +$1.82M 0.01% 1154
2023
Q4 		$2.38M Buy
268,362
+175,369
+189% +$1.35M 0.01% 1399
2023
Q3 		$887K Buy
+92,993
New +$1.21M ﹤0.01% 2005

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

John Overdeck's PRME Position: Q2 2026 in Review

John Overdeck reduced its Prime Medicine (PRME) stake by 3.1% in Q2 2026, selling an estimated $160K and leaving 1,524,511 shares worth $5.63M. The position accounts for ﹤0.01% of the portfolio, ranked #2026.

John Overdeck first reported a position in PRME in Q3 2023 and has held it in 12 quarters since. The position peaked at $5.65M in Q4 2025. 186 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • John Overdeck held 1,524,511 shares of Prime Medicine worth $5.63M as of Q2 2026.
  • John Overdeck sold 48,300 Prime Medicine shares in Q2 2026, an estimated $160K.
  • Prime Medicine made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #2026 holding.
  • John Overdeck first reported a position in Prime Medicine in Q3 2023 and has held it in 12 quarters since.
  • John Overdeck's Prime Medicine position peaked at $5.65M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.